Previous
Milestones
2008 was a year in which Abbott delivered strong performance and maintained leadership positions across its businesses, with a number of new product milestones.
Humira
Introduced two new Humira indications: moderate to severe chronic plaque psoriasis and polyarticular juvenile idiopathic arthritis. We also launched Humira for rheumatoid arthritis in Japan. Humira has helped hundreds of thousands of patients worldwide.
Similac
Advance
EarlyShield
Launched Similac Advance EarlyShield, the only infant formula that has a unique blend of prebiotics, nucleotides and antioxidants to support a baby’s natural immune system.
Trilipix
Expanded our cholesterol product portfolio with the FDA approval of Trilipix, the first fenofibrate with an indication for use in combination with statins to treat LDL, HDL and triglycerides. Combination treatment may potentially help patients better meet their lipid goals.
Xience V
Launched Xience V in the United States, where it quickly became the leading drug-eluting stent on the market, matching its success in Europe. We also submitted Xience V for approval in Japan.
Simcor
Launched Simcor, the first fixed-dose combination of two widely prescribed cholesterol therapies, Abbott’s Niaspan and simvastatin (generic Zocor).
FreeStyle
Freedom
Lite
Improved convenience for people with diabetes with the launch of FreeStyle Freedom Lite, our second no-coding blood glucose meter.
Architect
i1000SR
Introduced the
Architect i1000SR , an immunochemistry analyzer designed to improve productivity in small-volume clinical laboratories.
Page Top